Last reviewed · How we verify
Insulin glulisine TID
Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels.
Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin glulisine TID |
|---|---|
| Also known as | HMR1964, Device: Disposable self-injector prefilled pen (Apidra® Solostar®) |
| Sponsor | Sanofi |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin glulisine is a recombinant human insulin analog with rapid onset and short duration of action. It binds to the insulin receptor with similar affinity to human insulin but has faster absorption and earlier peak action, making it suitable for mealtime glucose control. It promotes glucose uptake into peripheral tissues and suppresses hepatic glucose production.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (PHASE4)
- Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM (NA)
- Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients (PHASE3)
- baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (PHASE4)
- Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (PHASE4)
- Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes (PHASE4)
- Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus (PHASE3)
- Insulin Glulisine in Diabetes Mellitus, Type 2 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin glulisine TID CI brief — competitive landscape report
- Insulin glulisine TID updates RSS · CI watch RSS
- Sanofi portfolio CI